Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.

Javier Rodriguez-CarrioAgata BurskaPhilip Gerard ConaghanWillem A DikRobert BiesenMaija-Leena ElorantaGiulio CavalliMarianne VisserDimitrios T BoumpasGeorge BertsiasMarie Wahren-HerleniusJan RehwinkelMarie-Louise FrémondMary K CrowLars RonnblomEd VitalMarjan Versnel

Published in: RMD open (2023)

Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.

Keyphrases

dendritic cells
high throughput
immune response
rheumatoid arthritis
risk assessment
drug induced